A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology
about
Development of Safe and Effective Botanical Dietary SupplementsPrediction of hepatic clearance in human from in vitro data for successful drug development.Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved PharmacokineticsDerivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities.Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm.Cytochrome P450 2C9-CYP2C9.Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5.Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage.In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substratesGenetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity.In vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies.Metabolic profiling of a novel antithrombotic compound, S002-333 and enantiomers: metabolic stability, species comparison and in vitro-in vivo extrapolation.Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies.Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.In vitro identification of human cytochrome P450 isoforms involved in the metabolism of Geissoschizine methyl ether, an active component of the traditional Japanese medicine Yokukansan.Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1'-hydroxylation.Modeling Drug Disposition and Drug-Drug Interactions Through Hypothesis-Driven Physiologically Based Pharmacokinetics: a Reversal Translation Perspective.
P2860
Q28833664-6FF32C8F-1BA5-4F54-8417-318128D4C718Q33437736-A42241A4-30E3-4F48-B6B6-9EAB1FF19C46Q35598226-B3A5E350-9183-4340-8A76-625ED75B0B5AQ35859325-B1C4F01E-B294-4B30-8FE0-2E8F2230B661Q36402091-62EFD319-DBF6-4937-B924-F672F3EBCA1AQ37691210-EBD28B3C-BA74-4BAB-885F-B99D3359FF48Q40282075-575AEBB6-1BAB-4C7C-A3F6-8C8E897B992EQ40300462-D65E6A95-E8E5-4C27-9065-487A3C3C911AQ41986948-F5BFC5FA-28F4-4031-86A2-D09BDFA50F2CQ43879115-BFCB9256-7168-45A2-9859-BC8F5FD4AF83Q43932208-0065F757-6534-4E56-B25E-2E63754E93ACQ46652380-2178A8ED-2EE0-46A3-9C93-2ABC6F1BF577Q47598236-F6764587-93F1-4D9F-A4F8-246249FD9974Q47628234-46DFF375-0499-46B3-87DF-00E443ACE60DQ47940552-EA5E3C6B-A52E-4173-AF84-4167FA036380Q48585391-301E78EE-63F0-478F-9FD9-17B463CEB914Q50076374-6A04BED4-0CD0-4960-8026-AA68EE3577AD
P2860
A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
A comparison of relative abund ...... zation of human CYP enzymology
@ast
A comparison of relative abund ...... zation of human CYP enzymology
@en
type
label
A comparison of relative abund ...... zation of human CYP enzymology
@ast
A comparison of relative abund ...... zation of human CYP enzymology
@en
prefLabel
A comparison of relative abund ...... zation of human CYP enzymology
@ast
A comparison of relative abund ...... zation of human CYP enzymology
@en
P2093
P2860
P1476
A comparison of relative abund ...... zation of human CYP enzymology
@en
P2093
Harry V Gelboin
Kristopher W Krausz
Matthew G Soars
Robert J Riley
P2860
P304
P356
10.1046/J.1365-2125.2003.01721.X
P407
P577
2003-02-01T00:00:00Z